Search results
Results from the WOW.Com Content Network
The FDA approved Xiaflex for the treatment of Peyronie’s disease in December 2013. Following this, Xiapex gained EU approval for the treatment of Peyronie’s disease in February 2015, making it the first and only biologic therapy indicated for the treatment of Peyronie's disease. [10]
Currently, Xiaflex is the only medication FDA-approved specifically for treating Peyronie’s disease. Interferon. This protein-based medication may help break down scar tissue that can develop in ...
Auxilium Pharmaceuticals , a $910 million biopharmaceutical company, announced today it is expanding a license agreement with BioSpecifics Technologies giving Auxilium the right to market Xiaflex ...
In February 2010 the US Food and Drug Administration (FDA) approved injectable collagenase extracted from Clostridium histolyticum for the treatment of Dupuytren's contracture in adults with a palpable Dupuytren's cord.
For premium support please call: 800-290-4726 more ways to reach us
From or to a drug trade name: This is a redirect from (or to) the trade name of a drug to (or from) the international nonproprietary name (INN).
In combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant ...
The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...